Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?

Van Dam D, Vermeiren Y, Dekker AD, Naudé PJ, Deyn PP.

Curr Alzheimer Res. 2016;13(10):1145-64. Review.

2.
3.

A disease modification effect of APOE E4 on the association between urinary albumin excretion and cognition in Korean adults.

Shin MH, Kweon SS, Choi JS, Lee YH, Nam HS, Park KS, Kim HN, Oh SY, Jeong SK.

Dis Markers. 2014;2014:724281. doi: 10.1155/2014/724281.

4.

Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease.

Giannoni P, Gaven F, de Bundel D, Baranger K, Marchetti-Gauthier E, Roman FS, Valjent E, Marin P, Bockaert J, Rivera S, Claeysen S.

Front Aging Neurosci. 2013 Dec 24;5:96. doi: 10.3389/fnagi.2013.00096.

5.

The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Swerdlow RH, Burns JM, Khan SM.

Biochim Biophys Acta. 2014 Aug;1842(8):1219-31. doi: 10.1016/j.bbadis.2013.09.010. Review.

6.

Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease.

Saido TC.

Proc Jpn Acad Ser B Phys Biol Sci. 2013;89(7):321-39. Review.

7.

Infantile exposure to lead and late-age cognitive decline: relevance to AD.

Bihaqi SW, Bahmani A, Subaiea GM, Zawia NH.

Alzheimers Dement. 2014 Mar;10(2):187-95. doi: 10.1016/j.jalz.2013.02.012.

8.

Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.

Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH.

Neurobiol Aging. 2013 Oct;34(10):2421-30. doi: 10.1016/j.neurobiolaging.2013.04.002.

9.

Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and amyloid precursor protein (AβPP) expression in rat brain.

Bihaqi SW, Singh AP, Tiwari M.

Indian J Pharmacol. 2012 Sep-Oct;44(5):593-8. doi: 10.4103/0253-7613.100383.

10.

Proteolytic degradation of amyloid β-protein.

Saido T, Leissring MA.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a006379. doi: 10.1101/cshperspect.a006379. Review.

11.

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

Cacabelos R, Martínez R, Fernández-Novoa L, Carril JC, Lombardi V, Carrera I, Corzo L, Tellado I, Leszek J, McKay A, Takeda M.

Int J Alzheimers Dis. 2012;2012:518901. doi: 10.1155/2012/518901.

12.

Lifespan brain activity, β-amyloid, and Alzheimer's disease.

Jagust WJ, Mormino EC.

Trends Cogn Sci. 2011 Nov;15(11):520-6. doi: 10.1016/j.tics.2011.09.004.

13.

Brain aging, Alzheimer's disease, and mitochondria.

Swerdlow RH.

Biochim Biophys Acta. 2011 Dec;1812(12):1630-9. doi: 10.1016/j.bbadis.2011.08.012. Review.

14.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG.

J Alzheimers Dis. 2011;24(2):315-25. doi: 10.3233/JAD-2011-101809.

15.

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations.

Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, LaDu MJ.

J Neurosci Methods. 2011 Mar 15;196(1):51-9. doi: 10.1016/j.jneumeth.2010.12.025.

16.

Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.

Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS.

J Neurochem. 2010 Oct;115(1):47-57. doi: 10.1111/j.1471-4159.2010.06899.x.

17.

APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging.

Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM.

Arch Neurol. 2010 Jan;67(1):93-8. doi: 10.1001/archneurol.2009.913.

18.

Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers.

Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, Cabeza R.

Alzheimers Dement. 2010 Jul;6(4):303-11. doi: 10.1016/j.jalz.2009.07.003.

19.

Neuronal death in Alzheimer's disease and therapeutic opportunities.

Donev R, Kolev M, Millet B, Thome J.

J Cell Mol Med. 2009 Nov-Dec;13(11-12):4329-48. doi: 10.1111/j.1582-4934.2009.00889.x. Review.

20.

Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM.

N Engl J Med. 2009 Jul 16;361(3):255-63. doi: 10.1056/NEJMoa0809437.

Supplemental Content

Support Center